Valganiclovir

Phase 2Small molecule

Valganiclovir is one of 4 small molecule programs targeting KSHV Inflammatory Cytokine Syndrome (KICS). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KSHV Inflammatory Cytokine Syndrome (KICS)Recruiting

KSHV Inflammatory Cytokine Syndrome (KICS)Phase 2

Recruiting

Competition

Competitive Landscape

3 competitors in KSHV Inflammatory Cytokine Syndrome (KICS)

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 2

1 2

Retrovir

BBp Consulting, Inc

Phase 2

1 3

Liposomal Doxorubicin

Eli Lilly

Phase 2

1 4

Valganiclovir

NNational Cancer Institute (NCI)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

KSHV Inflammatory Cytokine Syndrome (KICS)

NCT01419561

Clinical

Trials by Indication[1]

KSHV Inflammatory Cytokine Syndrome (KICS)1 trial

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01419561·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Valganiclovir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Valganiclovir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Valganiclovir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Valganiclovir

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

KSHV Inflammatory Cytokine Syndrome (KICS)1 trial

References

Drug Info

Quick Facts

Related News